Key result
Administration of dicumarol decreases cothromboplastin activity, causing a deficiency in the conversion of prothrombin to thrombin that precedes changes in prothrombin itself.
Why the study?
Does dicumarol administration affect co-thromboplastin activity and the conversion of prothrombin to thrombin?
Observational
Does dicumarol administration affect co-thromboplastin activity and the conversion of prothrombin to thrombin?
Dicumarol's anticoagulant effect involves a decrease in cothromboplastin activity that precedes the decline in prothrombin levels.
May prompt earlier coagulation monitoring beyond prothrombin time with dicumarol; leaves open validation in modern vitamin K antagonist regimens.
The deficiency in the conversion of prothrombin to thrombin which develops after administration of dicumarol appears to be due largely to decreased cothromboplastin activity. Both the development of this deficiency and the recovery from it tend to precede the accompanying changes in prothrombin itself, as measured by the two-stage method. In terms of deviation from normal, the deficiency in conversion often exceeds in magnitude the deficiency of prothrombin itself.
No takes yet. Share an insight, caveat, or question.
Mann et al. (1951) reported an observational. Dicumarol was evaluated on Co-thromboplastin activity and conversion of prothrombin to thrombin. Administration of dicumarol decreases cothromboplastin activity, causing a deficiency in the conversion of prothrombin to thrombin that precedes changes in prothrombin itself.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: